Can I read LB932 Dermatomyositis following treatment with cyclin-dependent kinases inhibitors: A single-center retrospective cohort study on EtoBox?

LB932 Dermatomyositis following treatment with cyclin-dependent kinases inhibitors: A single-center retrospective cohort study by A. Jfri; T. Harp; R. Vleugels; N. LeBoeuf; L. Guggina is a Medicine article available to read on EtoBox.

What is LB932 Dermatomyositis following treatment with cyclin-dependent kinases inhibitors: A single-center retrospective cohort study about?

Locally advanced basal cell carcinomas (LaBCCs) require multi-disciplinary treatment including surgery, radiation, and systemic therapy. There is limited real-world data on treatment patterns for these advanced tumors. A multicenter retrospective chart review was performed of all laBCCs. Tumors were included if they underwent advanced surgery (amputation, exenteration, bone resection, auriculectomy, excision on the face and scalp > 4 cm 2 ), radiotherapy, or systemic therapy. Data on achievement of no evidence of disease (NED) and poor outcomes (including local recurrence, nodal metastasis, distant metastasis, and disease-specific death) were collected. Cox proportional Hazard modelling was utilized to evaluate the impact of number of treatments required to clear the tumor on poor outcomes. A total of 494 laBCCs were identified, of which 414 (84%) achieved NED within the first three lines of treatment. 89 (21%) of tumors developed a poor outcome. 363 (73%) of tumors received surgery, 84 (17%) of tumors received radiation, and 47 (10%) of tumors received systemic therapy as first line treatment. 323 (65%) of tumors that required first line treatment, 78 (48%) of tumors that required

Who reads LB932 Dermatomyositis following treatment with cyclin-dependent kinases inhibitors: A single-center retrospective cohort study?

Author

A. Jfri; T. Harp; R. Vleugels; N. LeBoeuf; L. Guggina

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Medicine (Health Sciences)